Antarelix

Medicus Pharma (NASDAQ: MDCX) has announced a binding letter of intent to acquire Antev in a share exchange transaction valued at approximately US$75 million. The deal includes Antev shareholders receiving a ~19% equity stake (2,666,600 shares) in Medicus and up to US$65 million in contingent payments tied to FDA approvals. Antev is developing Teverelix, a next-generation GnRH antagonist, targeting two key markets: The transaction is expected to close by June 2025, subject to due diligence, definitive agreements, and regulatory approvals. Philadelphia, Pennsylvania--(Newsfile Corp. - April 28, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based late clinical-stage drug development company, announced today that they have entered into a binding letter of intent dated April 26, 2025 (the "Letter Agreement") pursuant to which Medicus has agreed to acquire all of the issued and outstanding shares of Antev (the "Antev Shares") on a share exchange basis (the "Transaction"). Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Subject to the assumptions, qualifications, and conditions noted in the Letter Agreement, Medicus will negotiate and enter into a definitive agreement with Antev to acquire all issued and outstanding Antev Shares, on a fully diluted basis, in exchange for 2,666,600 (or approximately 19% in aggregate) of the issued and outstanding Medicus common shares (the "Consideration Shares"). In addition to resale restrictions prescribed under applicable securities law, the Consideration Shares issuable to Antev shareholders will be subject to a 9-month staggered lock-up and an agreement granting certain voting rights in favor of Medicus management for a period of 36 months. Antev shareholders will be entitled to receive up to approximately US$65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals, as more particularly described in the Letter Agreement. The Transaction is expected to close before the end of June 2025, subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. "The LOI to acquire Antev represents strategic depth in our drug development program," stated Dr. Raza Bokhari, Executive Chairman & CEO. "Teverelix, a next generation GnRH antagonist, is relatively derisked and is well positioned to become first in class product to prevent acute urinary retention recurrence and treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing ~US$6 Billion in potential market opportunity."

The latest update is out from Medicus Pharma Ltd ( (MDCX) ). Medicus Pharma Ltd. has announced a binding letter of intent to acquire Antev Ltd., a UK-based clinical-stage biotech company, for approximately $75 million through a share exchange transaction. This acquisition is expected to enhance Medicus’s drug development program by incorporating Antev’s promising product, Teverelix, which targets acute urinary retention and high cardiovascular risk prostate cancer, potentially tapping into a $6 billion market opportunity. The transaction, which includes contingent payments and a significant equity stake for Antev shareholders, is anticipated to close by June 2025, subject to regulatory approvals and other conditions. Spark’s Take on MDCX Stock According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform. Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability. To see Spark’s full report on MDCX stock, click here. More about Medicus Pharma Ltd Medicus Pharma Ltd. is a pharmaceutical company that operates in the drug development industry. It focuses on developing innovative treatments for various medical conditions, with a particular emphasis on products that address unmet medical needs. YTD Price Performance: 62.55% Average Trading Volume: 61,743 Technical Sentiment Signal: Strong Sell Current Market Cap: $48.87M See more data about MDCX stock on TipRanks’ Stock Analysis page.